Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCARLET-2 study of ART-123 in sepsis with coagulopathy
2018-000246-19Phase 3Terminated
- Sponsor
- Asahi Kasei Corporation
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis and coagulopathy comparing ART-123 with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jun 2018; status: terminated.
02
Drugs
thrombomodulin alfa
03
Conditions
sepsiscoagulopathy
Beyond the preview
Go deeper on 2018-000246-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000246-19.